SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-030764
Filing Date
2021-02-05
Accepted
2021-02-05 16:43:54
Documents
13
Period of Report
2021-02-04
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d125174d8k.htm   iXBRL 8-K 24541
2 EX-99.1 d125174dex991.htm EX-99.1 41942
  Complete submission text file 0001193125-21-030764.txt   198339

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dnli-20210204.xsd EX-101.SCH 3099
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dnli-20210204_lab.xml EX-101.LAB 17373
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dnli-20210204_pre.xml EX-101.PRE 10972
6 EXTRACTED XBRL INSTANCE DOCUMENT d125174d8k_htm.xml XML 3248
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 21596613
SIC: 2836 Biological Products, (No Diagnostic Substances)